Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s share price shot up 66.8% on Friday . The stock traded as high as $0.46 and last traded at $0.46. 3,358 shares changed hands during mid-day trading, an increase of 281% from the average session volume of 882 shares. The stock had previously closed at $0.27.
Defence Therapeutics Stock Up 66.8 %
The stock has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $0.49.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
See Also
- Five stocks we like better than Defence Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- How to Effectively Use the MarketBeat Ratings Screener
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Golden Cross Stocks: Pattern, Examples and Charts
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
